News

Pharmabiz19h

Pasithea completes enrollment and initial dosing of first Cohort from its phase 1/1b trial of PAS-004 in adult NF1 patients

Pasithea completes enrollment and initial dosing of first Cohort from its phase 1/1b trial of PAS-004 in adult NF1 patients: Miami Saturday, August 2, 2025, 18:00 Hrs [IST] Pasith ...
Pharmabiz20h

US FDA approves SetPoint Medical’s novel neuroimmune modulation device, SetPoint System for rheumatoid arthritis

US FDA approves SetPoint Medical’s novel neuroimmune modulation device, SetPoint System for rheumatoid arthritis: Valencia, California Saturday, August 2, 2025, 17:00 Hrs [IST] ...
Pharmabiz21h

BioDuro & Atombeat enter strategic partnership to launch an AI-powered platform for accelerated peptide drug discovery

BioDuro & Atombeat enter strategic partnership to launch an AI-powered platform for accelerated peptide drug discovery: Irvine, California Saturday, August 2, 2025, 16:00 Hrs [IST ...
Pharmabiz21h

Marengo Asia Hospitals inks strategic clinical partnership with Metis – The Medicity Hospital, Varanasi

Marengo Asia Hospitals inks strategic clinical partnership with Metis – The Medicity Hospital, Varanasi: Our Bureau, Mumbai Saturday, August 2, 2025, 15:40 Hrs [IST] Marengo Asi ...
Pharmabiz22h

US FDA grants fast track designation to Revalesio’s lead investigational therapy, RNS60 to treat acute ischemic stroke

US FDA grants fast track designation to Revalesio’s lead investigational therapy, RNS60 to treat acute ischemic stroke: Tacoma, Washington Saturday, August 2, 2025, 15:00 Hrs [I ...
Pharmabiz23h

Plus Therapeutics’ subsidiary, CNSide to launch CNSide cerebrospinal fluid assay platform in US

Plus Therapeutics’ subsidiary, CNSide to launch CNSide cerebrospinal fluid assay platform in US: Houston Saturday, August 2, 2025, 14:00 Hrs [IST] Plus Therapeutics, Inc., a cli ...